Breaking News
POSITION PAPER | The Views of TIF on Advanced Therapy Medicinal Products (ATMPs)
INFOGRAPHICS | Mapping Blood Use in Patients with Thalassaemia Across the EU
EXCLUSIVE WEBINAR | Iron Load and the Importance of Reliable Monitoring in Haemoglobin Disorders
EDUCATIONAL WEBINAR FOR PATIENTS ON IRON OVERLOAD AND MONITORING | 21 November 2024
SICKLE CELL DISEASE | FDA Grants Orphan Drug Designation to AND017
TIF STUDY | Desferioxamine Usage Survey
COUNTRIES | The Maldives Launches Thalassaemia-Specialized Hospital and 10-Year Strategic Disease Plan
Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)
WHAT YOU NEED TO KNOW | EMA Recommends Suspension of Pfizer’s Sickle Cell Disease Drug Oxbryta
APLASTIC ANEMIA | Hetrombopag Achieves Significant Hematological Responses in Newly Diagnosed Patients
English
English
Ελληνικά
Français
Deutsch
Italiano
العربية
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country Work
Projects
Global Thalassaemia Review
COVID-19 Pandemic
Surveys
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
Home
/
Industry and Research Foundations
/
Sebia-Logo-1
Sebia-Logo-1
Back to top button
Close
Search for
